First human test of Pfizer's new cancer drug halted early
NCT ID NCT05233436
Summary
This was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07265028. It was given alone and in combination with another immunotherapy drug, sasanlimab, to a small group of people with advanced solid tumors that had stopped responding to other treatments. The main goal was to see how much of the drug the body could handle and to check for side effects, but the trial was terminated before completion.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
HonorHealth Scottsdale Shea Medical Center
Scottsdale, Arizona, 85260, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
The Cancer Institute Hospital of JFCR
Koto, Tokyo, 135-8550, Japan
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.